9 Meters Biopharma Overview
Latest ROE for 9 Meters Biopharma: 790.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow790.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
9 Meters Biopharma posts a ROE of 790.59%. That is above the Technology sector average of 47.89%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Technology stocks, a ROE near 47.89% is typical. 9 Meters Biopharma's 790.59% is higher that level. That is roughly 1551.0% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
9 Meters Biopharma's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 790.59%; use YoY and peer views to separate noise from signal.
Context for NMTR's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 47.89%), and (3) consistency with growth and profitability. This page covers the first two; 9 Meters Biopharma's other metric pages and overview cover the third.
Judging 9 Meters Biopharma against Technology peers is usually better than using a market-wide rule of thumb. Business models inside Technology are more comparable, which makes gaps in ROE easier to interpret. Start with 790.59% here, then scan peer and history charts to see if the gap is persistent.
